Congress Wealth Management LLC DE Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Congress Wealth Management LLC DE decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,073 shares of the company’s stock after selling 116 shares during the quarter. Congress Wealth Management LLC DE’s holdings in IDEXX Laboratories were worth $444,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $25,000. Rialto Wealth Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $415.87 on Friday. The company has a market cap of $33.71 billion, a P/E ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. The business has a fifty day simple moving average of $437.07 and a 200-day simple moving average of $443.27. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.